Drug Update · Endocrinology

Teplizumab (Tzield) FDA Expands Label to Delay C‑Peptide Decline in Pediatric Stage 3 T1D (0.13 pmol/mL)

September 09, 2026

FDA action date

June 12, 2026

Primary endpoint result (PROTECT)

Least-squares mean difference in stimulated C-peptide 0.13 pmol/mL (95% CI 0.09–0.17; P<0.001)

PROTECT enrollment

328 pediatric patients aged 8–17 years

Stage 3 dosing regimen (approved)

12-day IV course repeated at 6 months; BSA-based dosing Day1 106 mcg/m2; Day2 425 mcg/m2; Days3–12 850 mcg/m2

Clinical Perspective

Clinicians caring for pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D should be aware that Tzield now has an accelerated FDA indication to delay decline in endogenous insulin production in this population based on PROTECT C‑peptide results ^[4]^[6]^[7]. The approval supports consideration of teplizumab for eligible pediatric patients with recent Stage 3 T1D who meet the trial entry criteria, recognizing that the indication rests on a surrogate C‑peptide endpoint with an ongoing postapproval study to verify clinical benefit ^[4]^[6]^[3]^[7]. Will the ongoing confirmatory/postapproval studies verify a meaningful clinical benefit such as reduced insulin requirements or improved long‑term outcomes in this population?

Dr. Amit Desai, MBBS, MD (General Medicine), DM (Endocrinology) · Endocrinology

On June 12, 2026, the U.S. Food and Drug Administration granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years who were recently diagnosed with Stage 3 type 1 diabetes (T1D) ^[4]^[7]. The approval was based on the PROTECT randomized, double-blind, placebo-controlled trial in which teplizumab reduced the decline in stimulated C‑peptide by a least-squares mean difference of 0.13 pmol/mL versus placebo at Week 78 (95% CI, 0.09 to 0.17; P<0.001) ^[6]^[7].

Clinical Context

Teplizumab (Tzield) is a CD3-directed monoclonal antibody developed and marketed by Provention Bio (a Sanofi company) that targets CD3 on T lymphocytes and is described as delaying progression of type 1 diabetes through modulation of autoreactive T cells and increasing regulatory and exhausted CD8+ T‑cell populations in peripheral blood ^[7]^[1]. Tzield was previously approved to delay onset of Stage 3 T1D in adults and pediatric patients with Stage 2 T1D, and the June 12, 2026 action expands an accelerated approval to include delaying decline in endogenous insulin production in pediatric patients 8 to 17 years recently diagnosed with Stage 3 T1D based on a C‑peptide surrogate endpoint ^[4]^[7]. The FDA noted that the Stage 3 indication received accelerated approval and that a postapproval study is ongoing to verify clinical benefit ^[4]^[3]^[7].

Key Findings

The PROTECT study demonstrated that teplizumab reduced the decline in stimulated C‑peptide by a least-squares mean difference of 0.13 pmol/mL versus placebo at Week 78 (95% CI, 0.09 to 0.17; P<0.001) in pediatric patients 8 to 17 years of age recently diagnosed with Stage 3 T1D; this was the trial’s primary endpoint and supported the accelerated approval ^[6]^[7].
PROTECT enrolled 328 patients aged 8 to 17 years who had been diagnosed with Stage 3 T1D within the prior 6 weeks and retained residual beta‑cell function as indicated by peak stimulated C‑peptide >0.2 pmol/mL at baseline; treatment consisted of two 12‑day intravenous courses given approximately 6 months apart in the trial ^[5]^[6]^[7].
The FDA described the approval as accelerated and stated that continued approval may be contingent upon verification of clinical benefit in ongoing confirmatory trial(s) and postapproval obligations ^[4]^[2]^[7].

Safety & Tolerability

The prescribing information and FDA materials list a boxed warning for serious, life‑threatening viral reactivation, including Epstein‑Barr virus (EBV) and cytomegalovirus (CMV) reactivation; test patients for active EBV and CMV infection and confirm undetectable viral load prior to initiating Tzield, and monitor for signs and symptoms of viral reactivation during treatment and for at least 2 months after the last infusion ^[1]^[2]^[7].
Other named adverse reactions and laboratory abnormalities in labeling and FDA materials include lymphopenia, leukopenia, neutropenia, vomiting, rash, diarrhea, increased liver transaminases, and headache ^[1]^[2]^[5]^[6]^[7].
Monitoring recommendations in the labeling include obtaining a complete blood count and liver enzyme tests prior to initiation, monitoring lymphocyte counts regularly (every 2–3 days) during infusion, and discontinuing Tzield for prolonged severe lymphopenia (<500 cells per mcL lasting 1 week or longer) or for marked elevations in ALT/AST or bilirubin per prescribing guidance ^[1]^[2]^[7].

Study Design

The PROTECT study was a randomized, double‑blind, placebo‑controlled, multinational, multicenter phase 3 trial that enrolled 328 pediatric patients aged 8 to 17 years with Stage 3 T1D diagnosed within 6 weeks who had peak stimulated C‑peptide >0.2 pmol/mL; patients received a 12‑day IV course of teplizumab or placebo followed by a second 12‑day course approximately 6 months later, and the primary endpoint was change from baseline in stimulated C‑peptide at Week 78 ^[5]^[6]^[7]. The FDA granted accelerated approval for the Stage 3 pediatric indication on June 12, 2026, citing PROTECT results on the C‑peptide surrogate and required ongoing postapproval commitments to verify clinical benefit ^[4]^[3]^[7].

FAQ

Q1 What is Tzield (teplizumab) approved for?

Tzield is approved to delay the onset of Stage 3 type 1 diabetes in adult and pediatric patients 1 year of age and older with Stage 2 T1D, and—under accelerated approval—to delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years who were recently diagnosed with Stage 3 T1D. The pediatric Stage 3 approval was granted on June 12, 2026, and is based on a surrogate C‑peptide endpoint; continued approval may depend on verification of clinical benefit in postapproval studies.

Q2 How does teplizumab work?

Teplizumab is a CD3‑directed monoclonal antibody that binds CD3 on T lymphocytes and is described in labeling as delaying Stage 3 T1D and slowing decline in endogenous insulin production possibly via partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes, with increases in the proportion of regulatory T cells and exhausted CD8+ T cells observed in peripheral blood.

Q3 What is the recommended dosing regimen for pediatric Stage 3 T1D?

For pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D, the approved regimen in labeling is intravenous teplizumab once daily for 12 consecutive days for each treatment course, with a second 12‑day treatment course administered 6 months after the first course (if delayed, the second course may be given within 6 to 12 months after the first). The dosing is body surface area (BSA)‑based using the labeled per‑day mcg/m2 schedule: Day 1 106 mcg/m2; Day 2 425 mcg/m2; Days 3–12 850 mcg/m2. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the main safety concerns and common adverse reactions?

The prescribing information includes a boxed warning for serious life‑threatening viral reactivation, including EBV and CMV; evaluate patients for active EBV and CMV infection and confirm undetectable viral load before initiation and monitor for reactivation during treatment and for at least 2 months after the last infusion. Other named adverse reactions and lab abnormalities in labeling and FDA materials include lymphopenia, leukopenia, neutropenia, vomiting, rash, diarrhea, increased liver transaminases, and headache, and monitoring of complete blood count and liver enzymes is recommended prior to and during treatment.

Clinicians should consult current prescribing information for full dosing guidance.

Teplizumab (Tzield) FDA Expands Label to Delay C‑Peptide Decline in Pediatric Stage 3 T1D (0.13 pmol/mL)

Direct Clinical Takeaway & Evidence Summary

Teplizumab (Tzield) FDA Expands Label to Delay C‑Peptide Decline in Pediatric Stage 3 T1D (0.13 pmol/mL)

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Cite & Reference This Monograph

Get weekly clinical updates for Endocrinology in your inbox.

Related Clinical Updates

FDA Expands Tzield (teplizumab) Label to Stage 2 T1D ≥1 Year; TN-10 Shows HR 0.41 to Stage 3

FDA Approves Tirzepatide (Zepbound) for Chronic Weight Management: 18% Mean Weight Loss in Trial

Insulin Glargine: Langlara Approved; Semglee Interchangeable with Lantus

Verified HCP Portal